Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24876410 | 1.00 | MAPK13 (0.32) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL30129969 | 0.77 | HTR2A (0.34) | — | |
| SCHEMBL24876118 | 0.77 | HTR2A (0.34) | — | |
| SCHEMBL25066349 | 0.74 | MAPK13 (0.38) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL25066674 | 0.74 | MAPK13 (0.35) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL25066630 | 0.74 | MAPK13 (0.38) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL24876803 | 0.73 | MAPK13 (0.37) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL30913666 | 0.73 | MAPK13 (0.37) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL24876402 | 0.73 | MAPK13 (0.37) | MAPK13EIF2AK2MAPK12MAPK11MAPK14 | |
| SCHEMBL19743783 | 0.72 | ESR2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367117-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023283213-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-12 | — | — | WO | disclosed |